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Thrombocytosis is not an uncommon entity in children, but it occurs as a reactive change to a variety of conditions. Essential thrombocy-
themia is exceedingly rare in the pediatric age group. 
Among the myeloproliferative disorders in the pediatric 
age group, chronic myelogenous leukemia (CML) is the 
commonest, followed by polycythemia vera, essential 
thrombocytosis (ET), and myelofibrosis (MF). The 
incidence of essential thrombocythaemia is estimated 
to range from 1-4 cases per 10 million people younger 
than 20 years.1 It can affect any race or sex.
CASE
A 13-year-old girl presented with severe, global, rap-
idly worsening headache of 2 days duration without any 
history of head trauma, vomiting, fever, seizures, altered 
sensorium, neck stiffness or weakness in any part of the 
body. Past medical and surgical history was insignificant. 
Her physical examination, including central nervous 
system examination, was unremarkable. For the severe 
headache, she underwent an MRI of the brain, which 
showed a partial thrombus of the superior sagittal sinus 
(SSS) with mild engorgement of the venous channels of 
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both cerebral hemispheres (Figure 1). Subsequently MR 
venography of the brain confirmed thrombosis of SSS 
with partial thrombosis of right-sided transverse sinus. 
A complete blood count revealed a hemoglobin of 
12.5 g/dL, a total leucocyte count of 9×109/L, differen-
tial cell count of polymorphonuclear cells 65%, lympho-
cytes 30%, eosinophils 5%, and platelets of 943×109/L. 
A high platelet count with mild anisocytosis was also 
appreciated on the peripheral smear examination, which 
otherwise was unremarkable. Thrombocytosis was as-
sumed to be reactive to thrombosis. Erythrocyte sedi-
mentation rate, blood glucose, liver function tests, kidney 
function tests and iron profile were all within normal 
limits. Baseline prothrombin time (PT), activated partial 
thromboplastin time (aPTT) and fibrinogen levels were 
normal. The patient was screened for thrombophilia. The 
results of antithrombin, protein C, protein S, antiphos-
pholipid antibodies, homocysteine levels, apolipoprotein 
A/B, lupus anticoagulant, antinuclear antibodies were all 
normal and the patient was started on antithrombotics 
(subcutaneous low molecular weight heparin followed 
by Acenocoumarol and antiplatelet agents (aspirin). On 
follow up she showed regression of the superior sagittal 
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sinus thrombosis but thrombocytosis persisted. With no 
secondary cause apparent for persistent thrombocytosis, 
we looked for the JAK2 mutation (V617F), BCR-ABL 
fusion transcript. A bone marrow aspirate and biopsy 
were also performed. They showed a markedly increased 
number of mature megakaryocytes with hyperlobulated 
nuclei (some with a staghorn appearance), focal cluster-
ing and platelet pools. Overall, the bone marrow exami-
nation was consistent with essential thrombocythaemia 
(Figure 2, 3, 4). JAK2 mutation and BCR ABL were 
negative. Family screening for any thrombocytosis was 
negative. The patient fulfilled all the WHO 2008 diag-
nostic criteria for essential thrombocythaemia.
DISCUSSION
Essential thrombocythemia in children is of two types: 
i) familial ii) sporadic (nonfamilial). Familial ET in 
children are a heterogeneous group of disorders with 
different molecular abnormalities. Inheritance var-
ies; most familial thrombocythemia cases due to TPO 
gene mutations are transmitted in an autosomal domi-
nant manner, some are autosomal recessive and occa-
sionally it can be X-linked recessive. At least two classes 
of molecular mutations that lead to familial throm-
bocytosis are known. One involves mutations of the 
thrombopoietin (TPO) gene that result in increased 
TPO production by various mechanisms. The other in-
volves mutations of the C-MPL (TPO) receptor gene 
that somehow constitutively maintains activated signal 
transduction, leading to continuous signaling for mega-
karyocytic proliferation. In some families, no specific 
molecular abnormalities have been detected. 
In essential thrombocythemia, primary and second-
ary hypercoagulable states frequently lead to thrombot-
Figure 1. Mri brain showing superior sagittal sinus thrombosis 
(sagittal view).
Figure 2. Photomicrograph of bone marrow aspirate showing 
focal clustering of megakaryocytes (Wright giemsa, 40×).
Figure 3. Photomicrograph of bone marrow aspirate showing 
hyperlobulated megakaryocyte (staghorn nuclei), suggestive of 
essential thrombocytosis (Wright giemsa, 100×).
Figure 4. Bone marrow trephine biopsy showing increased 
megakaryocytes with some having staghorn appearance 
(Hematoxylin and eosin stain, 20×).
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ic episodes and to a hemorrhagic tendency. On the basis 
of experiences in young adults with essential thrombo-
cythemia, these complications may occur less often in 
children than in adults. Dame and Sutor reported that 
about 30% of children with essential thrombocytosis 
had thromboembolic or hemorrhagic complications 
at the time of diagnosis or later, and that about 20% 
of initially asymptomatic children had these complica-
tions later.2 These figures are similar to those of adults. 
Some studies have shown a lower rate of thrombosis.3 
Bleeding mainly involves the mucous membranes and 
skin (eg, GI hemorrhage, hemoptysis, post surgical 
bleeding, bruises, epistaxis). Thrombosis involves both 
veins and arteries and may affect the cerebral, coronary, 
and/or mesenteric arteries; the portal vein; and/or the 
inferior vena cava. A thrombotic event may, in fact, be 
the presenting symptom of ET. Classic erythromelalgia 
(throbbing, aching burning of palms and soles) associ-
ated with ET and polycythemia rubra vera has not been 
described in children. The complication rates in familial 
thrombocythemia are not well described due to its rar-
ity, but both thrombosis and hemorrhage occur.4 
For adults and some children with ET, various 
qualitative platelet abnormalities have also been found. 
Giant, bizarre-shaped platelets are seen on light micros-
copy. Platelets lack granules or are hypogranular. Often, 
megakaryocytic fragments are found in the blood smear. 
The bleeding time is usually normal. Platelet-function 
study shows loss of primary-wave and secondary-wave 
aggregation with epinephrine due to loss of membrane 
alpha-adrenergic receptors (this finding is most helpful 
in differentiating primary from secondary thrombocy-
tosis). In patients with non-familial primary thrombo-
cythemia, the plasma TPO level has been reported to be 
in the reference range or mildly elevated, whereas most 
patients with reactive thrombocytosis have an elevated 
level of TPO and interleukin (IL)-6 at least at the onset 
of the thrombocytosis-triggering event. In the familial 
form of ET, extremely elevated TPO indicates TPO 
mutation. In about 30% of pediatric cases, JAK2V617F 
mutation has been documented. Kurosawa H et al in 
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2009 found an association between cerebral venous si-
nus thrombosis in children with JAK2V617F mutation 
positivity in essential thrombocythemia.5
In a child with reactive thrombocytosis, drug ther-
apy is not required. Thrombohemorrhagic complica-
tions are exceedingly rare. The indications for treatment 
and the best treatment of children with ET are cur-
rently not known, and guidelines for the management 
of children with ET are needed. Familial thrombocy-
themia has a more benign course than sporadic ET. 
Symptomatic patients with ET should receive treat-
ment to lower their platelet count. For pediatric use, 
anagrelide or hydroxyurea is recommended. In a study 
by Harrison et al, adult patients (median age, about 60 
years) were randomly assigned to receive low-dose aspi-
rin plus hydroxyurea or anagrelide.6 Significantly more 
patients in the anagrelide arm than in the hydroxyurea 
arm reached the study endpoint. The authors conclud-
ed that hydroxyurea plus aspirin was more effective 
than anagrelide plus aspirin in preventing complica-
tions in adults with ET. Some recommend cytoreduc-
tive treatment for asymptomatic adult patients with 
platelet counts of more than 1.5 million/micro liter.7 
Radioactive phosphorus should not be used for young 
patients because of its carcinogenic potential.
Use of pharmacologic agents to prevent thrombotic 
complications in primary ET is controversial, because 
no laboratory studies offer predictive value in terms of 
the risk of thrombosis or hemorrhage. Tefferi et al rec-
ommend their use in only patients older than 60 years, 
in individuals with a history of thrombosis, or persons 
with cardiovascular risk factors, virtually eliminating 
pediatric patients.8 Patients who do develop a throm-
bus should be treated appropriately.
The prognosis of children with ET appears no dif-
ferent from that of adults. Adult patients have near-
normal life expectancy because of the low rate of leuke-
mic conversion. However, no child has been monitored 
long enough for that statement to be applicable to chil-
dren. The major morbidity factor is the increased risk 
of thrombohemorrhagic complications.
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